Trial Profile
A phase I study of PS-341 in pediatric patients with refractory solid tumours.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2013
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 16 Sep 2005 New trial record.